argenx SE: argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

argenx (ARGX) said its subsidiary Avena Merger Sub has started a tender offer to buy all outstanding Forte Biosciences (FBRX) shares for $77.00 per share in cash, net to the seller, under a July 26, 2026 merger agreement. The offer expires Aug. 26, 2026 unless extended, and Forte’s board recommends acceptance.

Original reporting
Published Aug 6, 2026, 12:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 1:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$ARGX
Bullish
medium confidence
Mentioned
$ARGX · $FBRX
Relevance
9/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$ARGXBullishHigh
01

Why it matters

The tender offer commencement is a primary M&A catalyst. Traders can model deal spread behavior using the fixed $77 cash consideration, the Aug. 26 expiration, and the HSR-related condition.

02

Market read

A fresh tender offer at a specified cash price with defined expiration and conditions typically drives immediate repricing and event-trade opportunities in both the acquirer and target.

03

What to watch

No financing condition is stated, but the minimum condition (tendered shares representing one more than 50% post-consummation) can still create execution risk and spread volatility if tendering lags.

Relevance 9/10Novelty 9/10Timing: tender offer commenced pre-market today; expiration set for Aug. 26, 2026 (unless extended)

Background

argenx and Forte entered a Merger Agreement dated July 26, 2026; this release announces the start of the tender offer and outlines merger mechanics and conditions.

Company-level read

Ticker impact

$ARGXBullishMedium confidence
Context

argenx commenced a tender offer via its subsidiary to acquire Forte, offering $77.00 per share in cash and setting deal conditions.

Expected impact

Likely positive bias for ARGX on deal momentum, with volatility around tender acceptance and regulatory/HSR timing.

Evidence & confidence

The article discloses a fresh tender offer commencement, a concrete bid price, and key conditions (including HSR waiting period), which typically drives immediate repricing and event-driven trading.

$FBRXBullishHigh confidence
Context

Forte is the target of argenx’s tender offer to purchase all outstanding shares for $77.00 per share, with expiration on Aug. 26, 2026.

Expected impact

Likely supportive for FBRX toward the $77 offer price, with potential premium/discount swings as deal conditions and extension risk evolve.

Evidence & confidence

The text provides the bid price, tender mechanics, and that Forte’s board recommends acceptance via a filed Schedule 14D-9, which are primary inputs for spread and arbitrage positioning.

Market effects

Reinforces ongoing consolidation in immunology/biopharma and may lift sentiment for similar small-to-mid cap targets.

Limited direct macro impact; primarily US biotech and European biotech M&A sentiment.

Moderate, as it is a single-company deal but can influence broader deal-risk appetite in biotech.

Counterpoint

Even with a stated $77 price, deal completion risk remains due to HSR waiting period expiration/termination and the minimum tender condition threshold.

Key entities

  • argenx

    Immunology company commencing the tender offer via a wholly-owned subsidiary.

  • Forte Biosciences, Inc.

    Clinical-stage biopharma company receiving the $77.00 per share cash tender offer.

  • Avena Merger Sub Inc.

    Wholly-owned subsidiary of argenx making the tender offer to purchase Forte shares.

  • Forte Board of Directors

    Published Schedule 14D-9 recommending Forte stockholders accept the offer.

Related articles

HighAI 9/10

Argenx: Up To $1.15 Billion Acquisition Of Unnatural Products To Expand Peptide Drug Discovery Platform

Argenx (ARGX) agreed to acquire Unnatural Products (UNP) for up to $1.15B, including $550M upfront. The deal expands Argenx's drug discovery platform to include macrocyclic peptides, potentially enabling oral and long-acting treatments. UNP's tech will complement Argenx's antibody engineering expertise. The transaction is expected to close by late 2026, subject to conditions.

$ARGXHighAI 9/10

Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition

Argenx (ARGX) agreed to acquire Unnatural Products (UNP) for up to $1.15B, combining UNP's peptide discovery platform with Argenx's immunology expertise. The deal includes $550M upfront and $595M in milestones. Argenx shares rose 5% on Euronext and 4% on Nasdaq following the announcement. Argenx's Vyvgart franchise reported $4.534B in net sales for 2026's first nine months, up 58% year-over-year.

HighAI 9/10

argenx to acquire biotech Unnatural Products for $1.15bn

argenx (ARGX) will acquire Unnatural Products (UNP) for up to $1.15bn, including $550m upfront. The deal adds macrocyclic peptide capabilities to argenx's immunology portfolio. UNP's team will continue operations in Santa Cruz, California, post-acquisition. The transaction is expected to close by year-end.

HighAI 9/10

Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition

Argenx acquires Unnatural Products (UNP) for $550M upfront, gaining oral peptide drug capabilities. UNP's macrocyclic peptides resist digestion, enabling oral administration. Argenx's Vyvgart had $4.5B sales in 2026, up 58.1%. The deal complements Argenx's antibody expertise and competes with big pharma in immunology. UNP could receive up to $595M in milestones.